Entering text into the input field will update the search result below

Imprimis Pharmaceuticals' (IMMY) CEO Mark Baum on Q4 2017 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY-OLD) Q4 2017 Earnings Conference Call March 8, 2018 4:30 PM ET


Mark Baum - Chief Executive Officer

Andrew Boll - Chief Financial Officer


Donald Besser - Manchester Management


Good afternoon and welcome to the conference call covering Imprimis Pharmaceuticals Financial Results and Business Update for the Fourth Quarter 2017. My name is Tim and I will be your operator for today's call.

At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. By now, you should have received a copy of the earnings press release. If you have not received a copy, please go to the Investor Relations page of the Company's website at www.imprimisrx.com.

Before we begin today, let me remind you that the Company's remarks include forward-looking statements within the meaning of the federal securities laws. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Imprimis' control, including risks and uncertainties described from time to time in its SEC filings, such as the risks and uncertainties related to Imprimis' ability to make commercially available its compounded formulations and technologies and FDA approval of certain drug candidates in a timely manner or at all.

For a list and description of those risks and uncertainties, please see the risk factors section of the Company's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission.

Imprimis' results may differ materially from those projected. Imprimis disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise.

This conference call contains time-sensitive information and is accurate only as of today. Additionally, Imprimis will refer to non-GAAP financial metrics, specifically adjusted EBITDA. A reconciliation of

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.